Plain-English translation of NCT06090864 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of cancer treatment called ATLCAR.CD30.CCR4 cells — your own immune cells that have been genetically modified in the laboratory to recognize and attack Hodgkin lymphoma. Doctors will take some of your blood cells, engineer them to target a protein found on lymphoma cells, and then give them back to you to fight the cancer. This treatment is designed for people whose lymphoma has come back or stopped responding to standard therapies.
Even with current treatments, Hodgkin lymphoma can be deadly in about 15% of patients, and standard therapies can cause lasting side effects. Doctors need new options that are both more effective and cause fewer long-term problems, which is why they're studying this new immunotherapy approach.
You likely qualify if…
You likely don't qualify if…
Your blood will be collected and sent to a laboratory where your immune cells are engineered over several weeks. During that time, your doctor may offer you standard cancer treatments to help control your disease. Once your cells are ready, you'll receive a short course of to prepare your body, then the engineered cells will be infused back into you. After that, you'll have regular follow-up visits to monitor how well the treatment works and watch for any side effects, with long-term follow-up required for 15 years.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States